Free Trial
The Market Does Not Wait. MarketBeat All Access for Just $149
Get the Deal
Claim MarketBeat All Access Sale Promotion

Ginkgo Bioworks (DNA) 10K Form and Latest SEC Filings 2026

Ginkgo Bioworks logo
$7.35 -0.02 (-0.26%)
Closing price 03:59 PM Eastern
Extended Trading
$7.44 +0.09 (+1.27%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest Ginkgo Bioworks SEC Filings & Recent Activity

Ginkgo Bioworks (NYSE:DNA) has submitted 1,231+ documents to the U.S. Securities and Exchange Commission (SEC) since 2020. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Ginkgo Bioworks's financial statements. The most recent filing was a Form SCHEDULE 13G/A submitted on May 15, 2026.

Form 4
Ginkgo Bioworks Holdings, Inc. Reports Ownership Change on Apr. 20, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Ginkgo Bioworks Files Current Report on Apr. 7, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-K
Ginkgo Bioworks Files Annual Report on Feb. 26, 2026

The 10-K contains Ginkgo Bioworks's audited financial statements, revenue, earnings, and risk factors for the prior fiscal year.

View earnings history

Ginkgo Bioworks SEC Filing History

Browse Ginkgo Bioworks' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
05/15/2026 4:48 PM
Ginkgo Bioworks (1830214) Subject
VIKING GLOBAL INVESTORS LP (1103804) Filed by
Form SCHEDULE 13G/A
05/13/2026 9:39 AM
Che Austin (1882820) Reporting
Ginkgo Bioworks (1830214) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/29/2026 3:18 PM
Ginkgo Bioworks (1830214) Filer
Form ARS
04/20/2026 4:02 PM
Coen Steven P. (1977441) Reporting
Ginkgo Bioworks (1830214) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/17/2026 2:37 PM
Coen Steven P. (1977441) Reporting
Ginkgo Bioworks (1830214) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/15/2026 8:37 AM
Che Austin (1882820) Reporting
Ginkgo Bioworks (1830214) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/14/2026 4:00 PM
Coen Steven P. (1977441) Reporting
Ginkgo Bioworks (1830214) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/13/2026 4:00 PM
Ginkgo Bioworks (1830214) Issuer
Shetty Reshma P. (1873523) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/13/2026 4:00 PM
Canton Barry (1882756) Reporting
Ginkgo Bioworks (1830214) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/13/2026 2:16 PM
Che Austin (1882820) Reporting
Ginkgo Bioworks (1830214) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/13/2026 2:17 PM
Coen Steven P. (1977441) Reporting
Ginkgo Bioworks (1830214) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/10/2026 4:01 PM
Ginkgo Bioworks (1830214) Issuer
Kelly Jason R (1845677) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/10/2026 4:01 PM
Canton Barry (1882756) Reporting
Ginkgo Bioworks (1830214) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/10/2026 4:02 PM
Ginkgo Bioworks (1830214) Issuer
Shetty Reshma P. (1873523) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/10/2026 2:46 PM
Ginkgo Bioworks (1830214) Subject
Shetty Reshma P. (1873523) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/09/2026 3:20 PM
Canton Barry (1882756) Reporting
Ginkgo Bioworks (1830214) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/08/2026 3:14 PM
Canton Barry (1882756) Reporting
Ginkgo Bioworks (1830214) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/08/2026 3:14 PM
Ginkgo Bioworks (1830214) Subject
Kelly Jason R (1845677) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/07/2026 4:02 PM
Ginkgo Bioworks (1830214) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/26/2026 5:36 PM
Ginkgo Bioworks (1830214) Subject
VANGUARD GROUP INC (102909) Filed by
Form SCHEDULE 13G/A
03/16/2026 3:13 PM
Coen Steven P. (1977441) Reporting
Ginkgo Bioworks (1830214) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/11/2026 9:14 AM
Che Austin (1882820) Reporting
Ginkgo Bioworks (1830214) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/26/2026 8:56 PM
Ginkgo Bioworks (1830214) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/26/2026 3:49 PM
Ginkgo Bioworks (1830214) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
02/26/2026 3:30 PM
Ginkgo Bioworks (1830214) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/26/2026 3:34 PM
Ginkgo Bioworks (1830214) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/05/2026 9:10 AM
BAILLIE GIFFORD & CO (1088875) Filed by
Ginkgo Bioworks (1830214) Subject
Form SCHEDULE 13G/A
02/04/2026 8:52 AM
Che Austin (1882820) Reporting
Ginkgo Bioworks (1830214) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/22/2026 3:12 PM
Coen Steven P. (1977441) Reporting
Ginkgo Bioworks (1830214) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/20/2026 3:15 PM
Coen Steven P. (1977441) Reporting
Ginkgo Bioworks (1830214) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/07/2026 9:09 AM
Che Austin (1882820) Reporting
Ginkgo Bioworks (1830214) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/23/2025 4:26 PM
Ginkgo Bioworks (1830214) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/16/2025 4:11 PM
Coen Steven P. (1977441) Reporting
Ginkgo Bioworks (1830214) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/10/2025 10:09 AM
Che Austin (1882820) Reporting
Ginkgo Bioworks (1830214) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/12/2025 9:06 AM
Che Austin (1882820) Reporting
Ginkgo Bioworks (1830214) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/06/2025 3:17 PM
Ginkgo Bioworks (1830214) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/06/2025 3:10 PM
Ginkgo Bioworks (1830214) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/21/2025 3:56 PM
Coen Steven P. (1977441) Reporting
Ginkgo Bioworks (1830214) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/21/2025 1:53 PM
Coen Steven P. (1977441) Reporting
Ginkgo Bioworks (1830214) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/21/2025 12:59 PM
Coen Steven P. (1977441) Reporting
Ginkgo Bioworks (1830214) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/08/2025 8:43 AM
Che Austin (1882820) Reporting
Ginkgo Bioworks (1830214) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
The 1934 playbook (Ad)

In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it coming — but those who did walked away wealthy.Trump holds that same legal authority today. Advisors close to the administration believe he may use it.If he does, the transfer moves fast. The window to position yourself on the right side is already closing.tc pixel

10/03/2025 4:01 PM
Coen Steven P. (1977441) Reporting
Ginkgo Bioworks (1830214) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/10/2025 3:06 PM
Ginkgo Bioworks (1830214) Issuer
HENRY CHRISTIAN O (1263805) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/10/2025 8:51 AM
Che Austin (1882820) Reporting
Ginkgo Bioworks (1830214) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/09/2025 10:06 AM
Ginkgo Bioworks (1830214) Subject
HENRY CHRISTIAN O (1263805) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/08/2025 11:19 AM
Ginkgo Bioworks (1830214) Subject
HENRY CHRISTIAN O (1263805) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/04/2025 3:54 PM
Ginkgo Bioworks (1830214) Filer
Form 424B5
08/29/2025 3:07 PM
Ginkgo Bioworks (1830214) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/26/2025 3:10 PM
Coen Steven P. (1977441) Reporting
Ginkgo Bioworks (1830214) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/14/2025 11:15 PM
Ginkgo Bioworks (1830214) Filer
Form EFFECT
08/06/2025 8:48 AM
Che Austin (1882820) Reporting
Ginkgo Bioworks (1830214) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/29/2025 12:34 PM
Ginkgo Bioworks (1830214) Subject
VANGUARD GROUP INC (102909) Filed by
Form SCHEDULE 13G
07/17/2025 6:54 PM
BlackRock, Inc. (2012383) Filed by
Ginkgo Bioworks (1830214) Subject
Form SCHEDULE 13G
07/09/2025 11:07 AM
Che Austin (1882820) Reporting
Ginkgo Bioworks (1830214) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/23/2025 8:54 AM
Che Austin (1882820) Reporting
Ginkgo Bioworks (1830214) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/20/2025 8:50 AM
Che Austin (1882820) Reporting
Ginkgo Bioworks (1830214) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/18/2025 8:41 AM
Che Austin (1882820) Reporting
Ginkgo Bioworks (1830214) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/17/2025 10:58 AM
Che Austin (1882820) Reporting
Ginkgo Bioworks (1830214) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/16/2025 9:21 AM
Che Austin (1882820) Reporting
Ginkgo Bioworks (1830214) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/13/2025 3:17 PM
Ginkgo Bioworks (1830214) Issuer
SLOAN HARRY (1258248) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2025 3:19 PM
Ginkgo Bioworks (1830214) Issuer
Hannan Kathy Hopinkah (1767813) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2025 3:24 PM
Ginkgo Bioworks (1830214) Issuer
POTTER MYRTLE S (1214130) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2025 9:04 AM
Che Austin (1882820) Reporting
Ginkgo Bioworks (1830214) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/12/2025 8:45 AM
Che Austin (1882820) Reporting
Ginkgo Bioworks (1830214) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/11/2025 8:58 AM
Che Austin (1882820) Reporting
Ginkgo Bioworks (1830214) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/10/2025 9:07 AM
Che Austin (1882820) Reporting
Ginkgo Bioworks (1830214) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/09/2025 9:01 AM
Che Austin (1882820) Reporting
Ginkgo Bioworks (1830214) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/06/2025 9:05 AM
Che Austin (1882820) Reporting
Ginkgo Bioworks (1830214) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/05/2025 9:20 AM
Che Austin (1882820) Reporting
Ginkgo Bioworks (1830214) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/04/2025 9:26 AM
Che Austin (1882820) Reporting
Ginkgo Bioworks (1830214) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/03/2025 9:08 AM
Che Austin (1882820) Reporting
Ginkgo Bioworks (1830214) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/02/2025 8:47 AM
Che Austin (1882820) Reporting
Ginkgo Bioworks (1830214) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/30/2025 8:40 AM
Che Austin (1882820) Reporting
Ginkgo Bioworks (1830214) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/29/2025 8:37 AM
Che Austin (1882820) Reporting
Ginkgo Bioworks (1830214) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/28/2025 8:36 AM
Che Austin (1882820) Reporting
Ginkgo Bioworks (1830214) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/27/2025 10:00 AM
Che Austin (1882820) Reporting
Ginkgo Bioworks (1830214) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/23/2025 8:55 AM
Che Austin (1882820) Reporting
Ginkgo Bioworks (1830214) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/22/2025 8:54 AM
Che Austin (1882820) Reporting
Ginkgo Bioworks (1830214) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/21/2025 8:54 AM
Che Austin (1882820) Reporting
Ginkgo Bioworks (1830214) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/20/2025 8:41 AM
Che Austin (1882820) Reporting
Ginkgo Bioworks (1830214) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/19/2025 10:03 AM
Che Austin (1882820) Reporting
Ginkgo Bioworks (1830214) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
(Data available from 1/1/2016 forward)

Ginkgo Bioworks SEC Filings - Frequently Asked Questions

Ginkgo Bioworks (DNA) has submitted 1,231+ filings to the SEC since 2020. You can browse the complete history or filter by form type using the tools above.

Ginkgo Bioworks's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on Ginkgo Bioworks's financial statements page.

The most recent filing was a Form SCHEDULE 13G/A submitted on May 15, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NYSE:DNA) was last updated on 5/19/2026 by MarketBeat.com Staff.
From Our Partners